World Health Organization Issues Alert Over Acute Shortage of Weight-Loss Injections
Less than a tenth of patients who could benefit from GLP-1 drugs like Wegovy are able to get them, states the World Health Organization as it publishes its inaugural recommendations on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for increased and just availability to this class of drugs.
Based on estimates, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"Our latest guidance affirms that excess weight is a long-term condition that can be treated with comprehensive and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are major hurdles to widespread availability to the injections that can aid individuals in losing substantial body mass, says the organization.
Skinny Jab Shortage
Despite the present best projected scenario, the production of such drugs could only cover around 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The guideline encourages nations and manufacturers to increase availability, through strategies like voluntary licensing.
A patent on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
The Way Obesity Drugs Operate
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, curb appetite and enhance the sense of being full so individuals eat less.
Individuals usually start to lose weight after several weeks of beginning the once-weekly jabs.
Evidence suggests users may regain a significant portion a year later of halting the drug, when their usual food cravings come back.
To be carrying excess weight increases your risk for contracting diseases, including type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity concerns individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, as per the health agency.
